The PRECISION Trial
This trial was designed to provide additional data on the Eversense CGM system across three metrics:
- →System accuracy within the first 30 days after Sensor insertion
- →Plasma dexamethasone concentration profiles after Sensor insertion
- →Additional safety and accuracy data for use up to 90 days
A total of 35 adults with Type 1 and Type 2 diabetes were inserted and evaluated. Glucose data was gathered in clinic at days 1, 7, 14, 30, 60 and 90. Results support the targeted indication, demonstrating the accuracy and safety of the Eversense CGM System for its intended use.
Number of Subjects
Precise II
90
adults
(≥ 18 years)
Total number of paired CGM and YSI reference
15,753
Percent within 15/15%
87%
Percent within 20/20%
94%
Percent within 30/30%
99%
Percent within 40/40%
100%
MARD
8.5%
Number of Subjects
Precision
35
adults
(≥ 18 years)
Total number of paired CGM and YSI reference
15,170
Percent within 15/15%
85%
Percent within 20/20%
93%
Percent within 30/30%
98%
Percent within 40/40%
99%
MARD
9.6%
The advanced sensor technology and under-the-skin sensor help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.